SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aurora Biosciences (ABSC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (38)10/28/1997 2:58:00 PM
From: Boyce Burge   of 359
 
Peter... ABSC's edge over the other screening cos is their ability to put a fluorescent reporter on a specific cell protein. The labeled protein can then report on specific and subtle ligand interactions in the living cell... i.e. cells are genetically modified in such a way that anything that perturbs, say, Ca++ binding in a specific cell compartment can be quickly screened.

This is a new and revolutionary approach to functional screening of lead compounds. But, the stock won't take off until some sensational lead compounds are actually identified using this approach. Arqule shot up last year based on such a "hit", using less revolutionary approaches.

As far as I know this big hit hasn't yet happened, but the rapid partnering with sophisticated pharmas suggests that this possibility is on everyone's mind. If we get such a "hit" the stock will be in the mid 20s overnight.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News